Recent Updates — ALKS
Alkermes plc announced positive topline results from a phase 1 proof-of-concept study evaluating ALKS 7290, an investigational orexin 2 receptor agonist for attention-deficit hyperactivity disorder (ADHD). The study enrolled 50 adults with ADHD and demonstrated dose-dependent, clinically meaningful improvements in symptoms at day 14. Median reductions from baseline were 14.0 points on the Adult ADHD Investigator Symptom Rating Scale (AISRS) for the 20 mg dose and 19.0 points for the 50 mg dose. The drug was generally well tolerated with no serious treatment-emergent adverse events reported. A phase 2 study is currently enrolling approximately 312 participants, with data expected in 2027. Alkermes plc operates as a global biopharmaceutical company developing innovative medicines in neuroscience.
Alkermes plc expanded its board of directors from ten to eleven members and appointed Anne C. Whitaker as an independent director, effective September 14, 2026. Ms. Whitaker will receive standard annual cash retainers and equity grants per the company's proxy statement, plus a new director award valued at $600,000 comprising stock options and restricted stock units vesting over three years. She brings extensive biopharmaceutical executive experience, having previously served as CEO of Aerami Therapeutics, Novoclem Therapeutics, and Synta Pharmaceuticals Corporation. Alkermes plc is a global biopharmaceutical company that develops innovative medicines in the field of neuroscience.
Alkermes plc entered into Amendment No. 1 to its Credit Agreement on August 12, 2026, reducing the interest rate spread by 0.75% for the Term Loan A facility and 0.50% for the Term Loan B facility. The amendment affects outstanding principal amounts of $745,312,500.00 and $773,062,500 respectively, with maturities in February and August 2031. This financial restructuring lowers borrowing costs without altering the total debt volume or triggering new equity issuance. Alkermes plc operates in the pharmaceutical industry, developing and commercializing medicines for central nervous system disorders.
Alkermes plc appointed Blair C. Jackson as President and Chief Executive Officer, effective August 1, 2026. The Board expanded the board size from nine to ten directors and elected Mr. Jackson to serve on the board and its Financial Operating Committee. His compensation package includes a $900,000 annual base salary and a target cash performance award equal to 100% of that salary. He received a one-time promotion equity award valued at $5 million, comprising approximately 55% performance-vesting restricted stock units with a three-year vesting period and 45% time-vesting stock options vesting over four years. Additionally, he was granted a special incentive performance equity award with a target value of $3 million in stock options vesting upon specific share price milestones after two years of service. The employment agreement provides for severance benefits equal to one-and-a-half times base salary and prior incentives if terminated without cause or for good reason, and double compensation following a change-in-control termination. Alkermes plc operates in the pharmaceutical industry, developing and commercializing treatments for addiction, mental health, and neurological disorders.
Alkermes plc reported second quarter 2026 total revenues of $496.0 million, a 27% increase from the prior year period, driven by strong proprietary product sales. GAAP net income was $0.5 million, while Adjusted EBITDA reached $139.2 million. The company announced that Blair Jackson will assume the role of Chief Executive Officer on August 1, 2026, succeeding Chairman Richard Pops, who will remain on the Board. Financial expectations for the full year 2026 were updated, with the GAAP net loss guidance widened to ($95)–($115) million from the previous ($70)–($90) million range, primarily due to a $26.4 million increase in the fair value of contingent consideration related to the Avadel acquisition. Alkermes operates in the biopharmaceutical industry, developing and commercializing innovative medicines in neuroscience.
Alkermes plc and Amneal Pharmaceuticals LLC terminated their Authorized Generic Product Supply Agreement dated September 9, 2025, regarding the distribution of an authorized generic version of VIVITROL in the United States. Amneal notified the Company after a failure to meet certain terms, which the Company did not incur any penalties for. Alkermes plc is a biopharmaceutical company focused on the development and commercialization of central nervous system and CNS-related products.